The Foundation for the National Institute of Health Seeks Public Comment - - BioPharm International

ADVERTISEMENT

The Foundation for the National Institute of Health Seeks Public Comment



The Observational Medical Outcomes Partnership (OMOP), a public–private partnership managed by the nonprofit Foundation for the National Institutes of Health and chaired by FDA, conducts methodological research on the use of observational healthcare data in studying the effects of medical products. The OMOP executive board is seeking public feedback on the priorities, infrastructure tasks, and research tasks it has proposed for 2013–2016.  Comments are being collected via the OMOP website through Sept. 15, 2012.

“Receiving public feedback regarding OMOP’s work is vital to our success,” said OMOP executive board member, Ronald Krall, MD, in an Aug. 27, 2012 press release. “We want to make sure we hear every idea about how to use healthcare data to improve the safety and effectiveness of medical products.”

OMOP was formed in 2008, and the group’s research since then has affirmed its belief that the science of observational research requires an empirical and reproducible approach to methodology and systematic application.  OMOP’s research has generated empirical evidence about the ability of observational analysis methods to identify true risks of medical products and discriminate from false findings.  Experiments were designed to understand how an estimated effect from an observational study relates to the true relationship between medical product exposure and adverse events.

Proposed priorities for upcoming research, described in the OMOP Call for Comments, include creating a foundation for the common representation of healthcare data, developing empirical evidence to support study of the association between medical interventions and adverse outcomes, developing empirical evidence to aid detection of unsuspected associations between medical events and interventions, and creating a framework for evidence-based decision making.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here